MX2009004170A - Materiales y metodos para inmunoglicoproteinas mejoradas. - Google Patents

Materiales y metodos para inmunoglicoproteinas mejoradas.

Info

Publication number
MX2009004170A
MX2009004170A MX2009004170A MX2009004170A MX2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A
Authority
MX
Mexico
Prior art keywords
castanospermine
dependent cytotoxicity
increasing antibody
immunoglycoproteins
antibody
Prior art date
Application number
MX2009004170A
Other languages
English (en)
Inventor
Baum Peter Robert
Thompson Peter Armstrong
Espling Erik Stephen
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of MX2009004170A publication Critical patent/MX2009004170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las inmunoglicoproteínas incluyen anticuerpos, con una ADCC (citotoxicidad dependiente de anticuerpos) mejorada y se proveen patrones de glicosilación alterados. También se proporcionan métodos de cultivo celular y los medios para producir tales inmunoglicoproteínas y usos terapéuticos de tales inmunoglicoproteínas.
MX2009004170A 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas. MX2009004170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85394406P 2006-10-24 2006-10-24
PCT/US2007/082343 WO2008052030A2 (en) 2006-10-24 2007-10-24 A method for increasing antibody-dependent cytotoxicity with castanospermine

Publications (1)

Publication Number Publication Date
MX2009004170A true MX2009004170A (es) 2009-06-26

Family

ID=39204867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004170A MX2009004170A (es) 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas.

Country Status (9)

Country Link
US (2) US20100150948A1 (es)
EP (1) EP2076538A2 (es)
JP (1) JP2010507394A (es)
CN (1) CN101646688A (es)
AU (1) AU2007308983B2 (es)
BR (1) BRPI0717601A2 (es)
CA (1) CA2663536A1 (es)
MX (1) MX2009004170A (es)
WO (1) WO2008052030A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
PL2282773T3 (pl) † 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
JP2014501097A (ja) * 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ, インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
EP2887947B1 (en) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease
SI3063287T1 (sl) * 2013-10-31 2025-06-30 Amgen, Inc. Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
JP6890581B2 (ja) 2015-08-28 2021-06-18 デビオファーム インターナショナル, エス. アー. Cd37の検出のための抗体およびアッセイ
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0503648B1 (en) * 1991-03-12 2000-06-07 Biogen, Inc. CD2-Binding domain of lymphocyte function associated antigen 3
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) * 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
PL213948B1 (pl) * 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
EP1689878A4 (en) * 2003-11-03 2007-02-14 Centocor Inc METHOD FOR MAINTAINING LOW SHEAR IN A BIOTECHNOLOGICAL SYSTEM
AU2006272555B2 (en) * 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
DK1945665T3 (da) * 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet

Also Published As

Publication number Publication date
AU2007308983A1 (en) 2008-05-02
BRPI0717601A2 (pt) 2013-10-22
US20130280240A1 (en) 2013-10-24
WO2008052030A3 (en) 2008-06-12
AU2007308983B2 (en) 2012-12-06
EP2076538A2 (en) 2009-07-08
CN101646688A (zh) 2010-02-10
WO2008052030A2 (en) 2008-05-02
JP2010507394A (ja) 2010-03-11
US20100150948A1 (en) 2010-06-17
CA2663536A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008052030A3 (en) A method for increasing antibody-dependent cytotoxicity with castanospermine
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
EP2007386A4 (en) CAMPTOTHECIN ANALOGUE HAVING A NEW LACTONE STABLE RETURNED "RETURNED" CORE AND METHODS FOR PREPARING AND USING SAME
EP2068389B8 (en) Method for producing separator for fuel cell, separator for fuel cell, and fuel cell
MX2007008506A (es) Metodos y productos para genotipificacion in vitro.
EP1901127A4 (en) BINDER RESIN FOR TONER, TONER AND PROCESS FOR PREPARING THE BINDER RESIN FOR TONER
MX300732B (es) Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
EP2094844A4 (en) IMPROVED BUTANOL PRODUCING MICROORGANISMS AND METHOD FOR THE PRODUCTION OF BUTANOL THEREWITH
IL180125A0 (en) Methods for producing biodiesel
IL197459A (en) Manned proteins, including antibodies, and methods for their preparation
EP2028172A4 (en) PROCESS FOR PRODUCING 1,3,3,3-TETRAFLUOROPROPENE
WO2009126350A3 (en) Methods and compositions for targeting k63-linked polyubiquitin
TWI318298B (en) Method for manufacturing a conductive contacter holder, and the conductive contacter holder
WO2007011742A3 (en) Cigs photovoltaic cells
AP2290A (en) Method of producing a booklet, data page produced by this method and booklet by the method.
EP2119518A4 (en) FINE SILVER POWDER
EP1911538A4 (en) EDGE REPLACEMENT CUTTING HEAD AND METHOD FOR PRODUCING THE SAME
MX2007004642A (es) Combinaciones polimericas para producir peliculas con un numero reducido de defectos.
EP2014824B8 (en) Reinforcing cord, method for producing the same, and product using the reinforcing cord
WO2008086228A3 (en) Arrays and methods for guided cell patterning
MX280092B (es) Proceso para producir un compuesto de 5 - hidroxi - 4 - tiometilpirazol.
WO2006044754A3 (en) Process for preparing telmisartan
PT2225314T (pt) Silicones-autoadesivos, método de fabrico, complexos que os utilizam e aplicações
PL1985176T3 (pl) Zabarwiona żyłka wędkarska i proces jej wytwarzania
SG129313A1 (en) Carbon black, method for producing the same, and its use

Legal Events

Date Code Title Description
FG Grant or registration